DK1496865T3 - Fremgangsmåde til fremstilling af krystaller, ifölge denne opnåelige krystaller og deres anvendelse i farmaceutiske formuleringer - Google Patents

Fremgangsmåde til fremstilling af krystaller, ifölge denne opnåelige krystaller og deres anvendelse i farmaceutiske formuleringer

Info

Publication number
DK1496865T3
DK1496865T3 DK03730046T DK03730046T DK1496865T3 DK 1496865 T3 DK1496865 T3 DK 1496865T3 DK 03730046 T DK03730046 T DK 03730046T DK 03730046 T DK03730046 T DK 03730046T DK 1496865 T3 DK1496865 T3 DK 1496865T3
Authority
DK
Denmark
Prior art keywords
crystals
mum
obtainable
preparation
pharmaceutical formulations
Prior art date
Application number
DK03730046T
Other languages
Danish (da)
English (en)
Inventor
Hagen Gerecke
Annette Eichardt
Sabine Gliesing
Uwe Mueller
Detlef Grawe
Peter Hoesel
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Application granted granted Critical
Publication of DK1496865T3 publication Critical patent/DK1496865T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK03730046T 2002-04-23 2003-04-22 Fremgangsmåde til fremstilling af krystaller, ifölge denne opnåelige krystaller og deres anvendelse i farmaceutiske formuleringer DK1496865T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10218109A DE10218109A1 (de) 2002-04-23 2002-04-23 Verfahren zum Herstellen von Kristallen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen

Publications (1)

Publication Number Publication Date
DK1496865T3 true DK1496865T3 (da) 2006-10-09

Family

ID=29264788

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03730046T DK1496865T3 (da) 2002-04-23 2003-04-22 Fremgangsmåde til fremstilling af krystaller, ifölge denne opnåelige krystaller og deres anvendelse i farmaceutiske formuleringer

Country Status (20)

Country Link
US (1) US7192942B2 (pl)
EP (1) EP1496865B1 (pl)
JP (1) JP4490114B2 (pl)
KR (1) KR20040106379A (pl)
CN (1) CN1646101A (pl)
AT (1) ATE332686T1 (pl)
AU (1) AU2003240652A1 (pl)
BR (1) BR0308744A (pl)
CA (1) CA2479991C (pl)
DE (2) DE10218109A1 (pl)
DK (1) DK1496865T3 (pl)
ES (1) ES2268368T3 (pl)
IL (1) IL163985A0 (pl)
MX (1) MXPA04010468A (pl)
NO (1) NO20045073L (pl)
PL (1) PL371339A1 (pl)
PT (1) PT1496865E (pl)
RU (1) RU2314315C2 (pl)
WO (1) WO2003090714A1 (pl)
ZA (1) ZA200409395B (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10218107A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen von Steroiden, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
US20090087492A1 (en) * 2006-03-14 2009-04-02 Merck & Co., Inc. Processes and Apparatuses for the Production of Crystalline Organic Microparticle Compositions by Micro-Milling and Crystallization on Micro-Seed and Their Use
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
RU2464321C2 (ru) * 2010-12-20 2012-10-20 Федеральное государственное образовательное учреждение высшего профессионального образования "Вологодская государственная молочнохозяйственная академия им. Н.В. Верещагина" Способ производства молочного сахара
RS62297B1 (sr) 2011-11-23 2021-09-30 Therapeuticsmd Inc Prirodne kombinovane hormonske supstitucione formulacije i terapije
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
EP4151219A4 (en) 2020-05-15 2024-05-15 Shionogi & Co., Ltd DRUG COMPOSITION WITH INHIBITED IMPURITIES PRODUCTION

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD275398B5 (de) 1988-09-07 1993-12-23 Dresden Arzneimittel Verfahren zur herstellung von feinverteilten pharmazeutischen wirkstoffen
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
NZ248813A (en) * 1992-11-25 1995-06-27 Eastman Kodak Co Polymeric grinding media used in grinding pharmaceutical substances
DE4332283A1 (de) * 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
KR0151363B1 (ko) * 1993-12-27 1998-10-01 시모무라 스스무 4-히드록시-4'-이소프로폭시디페닐 술폰 현상조성물, 습식분쇄방법, 및 분산액
US5718388A (en) * 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
US5534270A (en) * 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
AU8145198A (en) 1997-06-16 1999-01-04 Vertex Pharmaceuticals Incorporated Methods of increasing the bioavailability of stable crystal polymorphs of a compound
CN1183102C (zh) * 1998-12-25 2005-01-05 第一精密化学株式会社 泛酸钙的制备方法
EP1157996A1 (de) * 2000-05-23 2001-11-28 JENAPHARM GmbH Neue Festkörperformen des Mesoprogestins 11Beta-[4E-(Hydroxyiminomethyl)-phenyl]-17Alpha-methoxymethyl-17Beta-methoxy-estra-4,9-dien-3-on
DE10218107A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen von Steroiden, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen

Also Published As

Publication number Publication date
ATE332686T1 (de) 2006-08-15
PL371339A1 (pl) 2005-06-13
DE10218109A1 (de) 2003-11-20
CA2479991A1 (en) 2003-11-06
JP2005523333A (ja) 2005-08-04
RU2314315C2 (ru) 2008-01-10
WO2003090714A1 (de) 2003-11-06
JP4490114B2 (ja) 2010-06-23
US7192942B2 (en) 2007-03-20
BR0308744A (pt) 2005-01-11
RU2004134327A (ru) 2006-02-27
ZA200409395B (en) 2006-02-22
IL163985A0 (en) 2005-12-18
ES2268368T3 (es) 2007-03-16
CN1646101A (zh) 2005-07-27
AU2003240652A1 (en) 2003-11-10
CA2479991C (en) 2010-06-22
US20030225050A1 (en) 2003-12-04
EP1496865B1 (de) 2006-07-12
PT1496865E (pt) 2006-10-31
DE50304230D1 (de) 2006-08-24
EP1496865A1 (de) 2005-01-19
NO20045073L (no) 2004-11-22
KR20040106379A (ko) 2004-12-17
MXPA04010468A (es) 2004-12-13

Similar Documents

Publication Publication Date Title
NO20045073L (no) Fremgangsmate for fremstilling av krystaller, derved oppnaelige krystaller og deres anvendelse i farmasoytiske formuleringer
DK1140945T3 (da) Kondenserede 1,2,4-thiadiazinderivater, deres fremstilling og anvendelse
SI1358184T1 (sl) N-(3,3-dimetilindolin-6-il)(2-((4-piridilmetil)amino) (3-piridil))karboksamid in njegovi farmacevtski sestavki
NO20021859D0 (no) Nye digosakkarider, deres fremstilling samt farmasöytiske preparater
BR0013277A (pt) Derivados de 3(5) ureido-pirazol, processo para sua preparação e uso dos mesmos como agentes antitumorais
SI1427708T1 (sl) Derivati amino-ftalazinona kot zaviralci kinaze, postopek za njihovo pripravo in farmacevtski sestavki, ki jih vsebujejo
DK0503548T3 (da) Cykliske ureaderivater, lægemidler indeholdende disse, og fremgangsmåde til deres fremstilling.
IS7965A (is) Þíenópýrimidíndíón og notkun þeirra í breytingu ásjálfsnæmissjúkdómi
WO2002068406A3 (en) Substituted amine derivatives and their use for the treatment of angiogenesis
NO20062020L (no) 1-amino-2-oksysubstituerte tetrahydronaftalenderivater, fremgangsmate for fremstilling derav, og deres anvendelse som antiflogistika
DK1497308T3 (da) Fremgangsmåde til fremstilling af krystaller af steroider, krystaller opnået ved hjælp heraf og anvendelse heraf i farmaceutiske formuleringer
DK1517890T3 (da) Kationisk substituerede diphenylazetidinoner, fremgangsmåde til deres fremstilling, lægemidler indeholdende disse forbindelser og deres anvendelse
MX2023011408A (es) Compuestos de oxoisoindolina sustituidos con piridinilo para el tratamiento de cancer.
EA200101203A1 (ru) Производные пурина
DK0434057T3 (da) Indocarbazol-derivater, fremgangsmåder til deres fremstilling og deres anvendelse
DK0521768T3 (da) Nye triazolopyrimidin-derivater som er angiotensin II-receptor-antagonister, fremgangsmåder til deres fremstilling og farmaceutiske præparater med indhold deraf
DK0862577T3 (da) Sulfamatderivater af 1,3,5(10)-estratrien-derivater, fremgangsmåde til deres fremstilling og farmaceutiske præparater, der
NO995431D0 (no) Substituerte 3,3-diamino-2-propennitriler, deres fremstilling og anvendelse
EA200400690A1 (ru) Нуклеозиды, их препараты и их применение в качестве ингибиторов вирусных рнк-полимераз
EA200600046A1 (ru) Производные 6-[2-(фосфонометокси)алкокси]пиримидинов (варианты), способ их получения (варианты), фармацевтическая композиция на их основе и способ лечения вирусной инфекции
BR0318521A (pt) arilindenopiridinas e arilindenopirimidinas e métodos terapêuticos e profiláticos relacionados
NO20041573L (no) Aralkyl-tetrahydro-pyridiner, deres fremstilling og farmasoytiske preparater inneholdende de samme
NO870228L (no) Benzimidazolderivater, fremgangsmaate til deres fremstilling og anvendelse av forbindelsene fremstilt ved fremgangsmaaten.
NO20045071L (no) Fremgangsmate for fremstilling av krystaller ut i fra aktive legemiddelvirkestoffer, krystaller oppnadd derav og deres anvendelse i farmasoytiske formuleringer
NO20030801L (no) Aminoalkenylbenzoyl-benzofuran- eller benzotiofenderivater, fremgangsmåte for deres fremstilling og preparater inneholdende de samme